Zhitong Finance App News, Nuocheng Jianhua (688428.SH) issued an announcement. In the phase II/III adaptive clinical study of the next-generation highly selective oral tyrosine kinase 2 (“TYK2”) inhibitor soficitinib (ICP-332) independently developed by the company to treat patients with non-segmental vitiligo (NSV), phase II successfully reached the main end point and achieved positive top line results.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.